These preliminary results indicate fluphenazine may target the Akt and Wnt signaling pathways, that in turn can affect the expression of important downstream proteins such as β-catenin, FoxO1, BAD, and mTOR, ultimately regulating molecular processes related to cell metabolism, cell survival, apoptosis, etc. The in vivo results demonstrate this drug is a potent inhibitor of tumor growth and can decrease the metastasizing of cancer cells, although with some side effects associated. The gene discussed is AKT1; the disease is neoplasm.